Particulars (Rs. in cr) | Q1FY25 | Q1FY24 | YoY (%) | Q4FY24 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 720.00 | 467.00 | 54.00% | 551.00 | 31.00% |
EBITDA | 249.00 | 171.00 | 46.00% | 149.00 | 67.00% |
EBITDA Margin (%) | 34.58% | 36.62% | (204 bps) | 27.04% | 754 bps |
PAT | 89.00 | 93.00 | -4.00% | 79.98 | 11.00% |
EPS (Rs.) | 6.11 | 6.97 | -12.00% | 5.22 | 17.00% |
Source: Company Filings; stockaxis Research
Q1FY25 Result Highlights
Eris Lifesciences delivered in-line numbers for the quarter ended Q1FY25. Consolidated
net sales rose 54% YoY to Rs.720 cr aided by integration of Swiss parental and Biocon’s
nephro and derma business. Among various business acquired in FY24 - Biocon Nephro
and derma business reported 25% YoY growth, Swiss Parenterals reported Rs730mn of
revenues and Biocon branded formulation business grew by 13% YoY in Q1. Gross Margin
is down by 829 bps in Q1 due to significant changes in product/ business mix. However,
consolidated EBITDA witnessed a significant growth of 47% YoY to Rs.249 cr. OPM
came in at 34.5%. The YoY decline of 180bps was on account of integration of Biocon
and Swiss Parenteral business. Base business OPM stood at 39%. PAT fell 4% YoY to
Rs.89 cr reflects impact of all acquisitions and increase in book tax rate.
Net Debt of the company as on 30th June = INR 2,737 crores
DOMESTIC BRANDED FORMULATIONS – BASE BUSINESS HIGHLIGHTS (AWACS)
Base Business Q1 Financial Performance
BIOCON 1 – BUSINESS SEGMENT
BIOCON 2 BUSINESS SEGMENT
Marks the addition of two more power brands to our “100+ crores club” – bringing the total of our “100+ crores” brands to Five
SWISS PARENTALS
Key Conference call takeaways
Base Business
Biocon Business
Swiss Parentals
Guidance – Management has guided for Rs.3000 cr+ revenues with EBITDA of 35% in FY25.
Capex pegged at Rs.100-120 cr. for Hormones, Insulins & MABs.
Biocon 1 Business Segment (Guidance for FY25)
Biocon 2 Business Segment (Guidance for FY25)
Other Key takeaways
Eris Lifesciences reported in-line set of earnings for the quarter ended Q1FY25. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to sustain at +35% as revenue scales up from recent acquisitions which is currently operating at sub optimal profitability. Acquisitions, including Swiss Parenterals and Biocon's injectable business, are expected to contribute to ERIS growth trajectory in the medium term. ERIS is also working on launching over 20 'first-to-market' products, showcasing a strong focus on innovation. The company's robust product pipeline and expected patent expirations in key therapeutic areas contribute to a positive outlook. ERIS Lifesciences Ltd exhibits strong growth potential, driven by its innovative product pipeline, strategic acquisitions, and anticipated performance in key therapeutic segments.
The company has multiple growth levers such as broad-based offerings in the derma segment, opportunities in cardio metabolic market with patent expirations, and benefits of operating leverage, as revenue scales up from these acquisitions. We expect ERIS to outperform the industry over the near to medium term, as it has established its presence in the cardiac/ant diabetic segments. Additionally, the new product pipeline and patent expiries provide robust growth visibility in the future. Through the organic and inorganic routes, ERIS has enhanced its offerings in dermatology, nephrology, women’s healthcare, injectables, and intensified its diabetology/cardio-vascular portfolio. At CMP of Rs.1195, the stock is trading at 30x FY26E. We maintain HOLD rating on the stock.
Particulars (Rs. in cr) | Q1FY25 | Q1FY24 | YoY (%) | Q4FY24 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 720.00 | 467.00 | 54.00% | 551.00 | 31.00% |
COGS | 181.00 | 78.00 | 132.00% | 118.00 | 53.00% |
Gross Profit | 539.00 | 389.00 | 39.00% | 433.00 | 24.00% |
Gross Margin (%) | 74.86% | 83.30% | (844 bps) | 78.58% | (372 bps) |
Employee Benefit expenses | 133.00 | 104.00 | 28.00% | 102.00 | 30.00% |
Other expenses | 157.00 | 114.00 | 38.00% | 182.00 | -14.00% |
EBITDA | 249.00 | 171.00 | 46.00% | 149.00 | 67.00% |
EBITDA Margin (%) | 34.58% | 36.62% | (204 bps) | 27.04% | 754 bps |
Depreciation and amortisation expenses | 76.00 | 41.00 | 85.00% | 54.00 | 41.00% |
EBIT | 173.00 | 130.00 | 33.00% | 95.00 | 82.00% |
Finance cost | 60.00 | 17.00 | 253.00% | 33.00 | 82.00% |
Other Income | 2.00 | 1.00 | 100.00% | 15.00 | -87.00% |
PBT | 115.00 | 112.00 | 3.00% | 77.00 | 49.00% |
Tax expenses | 26.00 | 19.00 | 37.00% | -2.98 | - |
PAT | 89.00 | 93.00 | -4.00% | 79.98 | 11.00% |
EPS (Rs.) | 6.11 | 6.97 | -12.00% | 5.22 | 17.00% |